Inhibition of SARS-CoV-2 by type I and type III interferons.
Animals
Antiviral Agents
/ pharmacology
Betacoronavirus
/ drug effects
COVID-19
Cell Line
Chlorocebus aethiops
Coronavirus Infections
/ pathology
Humans
Interferon Type I
/ pharmacology
Interferons
/ pharmacology
Janus Kinases
/ metabolism
Nitriles
Pandemics
Pneumonia, Viral
/ pathology
Pyrazoles
/ pharmacology
Pyrimidines
Severe acute respiratory syndrome-related coronavirus
/ drug effects
SARS-CoV-2
Signal Transduction
/ drug effects
Vero Cells
Virus Replication
/ drug effects
Interferon Lambda
COVID-19
SARS–CoV-2
antiviral agent
cytokine action
infection
innate immunity
interferon
interferon-alpha/beta
interferon-lambda
ruxolitinib
virology
virus
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
09 10 2020
09 10 2020
Historique:
received:
07
04
2020
revised:
24
06
2020
pubmed:
27
6
2020
medline:
22
10
2020
entrez:
27
6
2020
Statut:
ppublish
Résumé
The recently emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative agent of the devastating COVID-19 lung disease pandemic. Here, we tested the inhibitory activities of the antiviral interferons of type I (IFN-α) and type III (IFN-λ) against SARS-CoV-2 and compared them with those against SARS-CoV-1, which emerged in 2003. Using two mammalian epithelial cell lines (human Calu-3 and simian Vero E6), we found that both IFNs dose-dependently inhibit SARS-CoV-2. In contrast, SARS-CoV-1 was restricted only by IFN-α in these cell lines. SARS-CoV-2 generally exhibited a broader IFN sensitivity than SARS-CoV-1. Moreover, ruxolitinib, an inhibitor of IFN-triggered Janus kinase/signal transducer and activator of transcription signaling, boosted SARS-CoV-2 replication in the IFN-competent Calu-3 cells. We conclude that SARS-CoV-2 is sensitive to exogenously added IFNs. This finding suggests that type I and especially the less adverse effect-prone type III IFN are good candidates for the management of COVID-19.
Identifiants
pubmed: 32587093
pii: S0021-9258(17)49795-X
doi: 10.1074/jbc.AC120.013788
pmc: PMC7549028
doi:
Substances chimiques
Antiviral Agents
0
Interferon Type I
0
Nitriles
0
Pyrazoles
0
Pyrimidines
0
ruxolitinib
82S8X8XX8H
Interferons
9008-11-1
Janus Kinases
EC 2.7.10.2
Interferon Lambda
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13958-13964Informations de copyright
© 2020 Felgenhauer et al.
Déclaration de conflit d'intérêts
Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.
Références
JAMA. 2003 Dec 24;290(24):3222-8
pubmed: 14693875
Cell Host Microbe. 2016 Feb 10;19(2):181-93
pubmed: 26867177
J Gen Virol. 2012 Dec;93(Pt 12):2601-2605
pubmed: 22956738
J Virol. 2020 Nov 9;94(23):
pubmed: 32938761
J Gen Virol. 1987 Mar;68 ( Pt 3):945-8
pubmed: 3029315
PLoS Med. 2006 Sep;3(9):e343
pubmed: 16968120
Lancet. 2003 Jul 26;362(9380):293-4
pubmed: 12892961
N Engl J Med. 2003 May 15;348(20):1967-76
pubmed: 12690091
Adv Virus Res. 2016;96:29-57
pubmed: 27712627
Adv Virus Res. 2016;96:219-243
pubmed: 27712625
Cell Host Microbe. 2020 Mar 11;27(3):325-328
pubmed: 32035028
PLoS Pathog. 2010 Apr 08;6(4):e1000849
pubmed: 20386712
J Virol. 2013 May;87(9):5300-4
pubmed: 23449793
EMBO J. 2013 Nov 27;32(23):3055-65
pubmed: 24169568
N Engl J Med. 2002 Sep 26;347(13):975-82
pubmed: 12324553
Lancet Infect Dis. 2014 Nov;14(11):1090-1095
pubmed: 25278221
Cell Rep. 2020 Jul 7;32(1):107863
pubmed: 32610043
Infect Disord Drug Targets. 2014;14(1):37-43
pubmed: 25019238
Antiviral Res. 2020 Jul;179:104811
pubmed: 32360182
Nat Rev Immunol. 2019 Oct;19(10):614-625
pubmed: 31201377
Trends Immunol. 2017 Aug;38(8):542-557
pubmed: 28579323
Nat Immunol. 2015 Aug;16(8):802-9
pubmed: 26194286
mBio. 2013 Feb 19;4(1):e00611-12
pubmed: 23422412
J Virol. 2013 Jun;87(12):6604-14
pubmed: 23552422
PLoS Pathog. 2008 Sep 12;4(9):e1000151
pubmed: 18787692
J Virol. 2010 Sep;84(18):9140-8
pubmed: 20592090
J Virol. 2010 Jun;84(11):5670-7
pubmed: 20335250
J Interferon Cytokine Res. 2019 Oct;39(10):586-591
pubmed: 30998425
Nat Biotechnol. 2011 Oct 30;29(11):1046-51
pubmed: 22037378
Lancet Infect Dis. 2020 Apr;20(4):400-402
pubmed: 32113509
J Interferon Cytokine Res. 2019 Oct;39(10):661-667
pubmed: 31120365
Clin Infect Dis. 2020 Apr 15;70(9):1837-1844
pubmed: 31925415
J Clin Virol. 2004 Jul;30(3):211-3
pubmed: 15135736
PLoS Pathog. 2018 Nov 28;14(11):e1007420
pubmed: 30485383
Immunity. 2019 Apr 16;50(4):907-923
pubmed: 30995506
Int J Antimicrob Agents. 2020 Aug;56(2):106023
pubmed: 32450201
J Exp Med. 2020 May 4;217(5):
pubmed: 32289152
Sci Rep. 2013;3:1686
pubmed: 23594967
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
J Hepatol. 2014 Dec;61(6):1238-46
pubmed: 25064437
J Interferon Cytokine Res. 2015 Apr;35(4):252-64
pubmed: 25714109
Nat Med. 2004 Mar;10(3):290-3
pubmed: 14981511
J Infect Dis. 2004 Apr 1;189(7):1164-7
pubmed: 15031783
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859